Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elbasvir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Elbasvir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elbasvir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elbasvir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

    NCT03365635 · start 2019-09-22

    Registered record
    Registry ID
    NCT03365635
    Conditions
    Hepatitis C; Hemodialysis; Nosocomial Infection
    Interventions
    Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-09-22
    Completion
    2020-09-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Hemodialysis; Nosocomial Infection
    InterventionElbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
    PhasePhase 4
    Registry statusCompleted

  • Zepatier in Patients with Substance Use

    NCT04048850 · start 2019-09-20

    Registered record
    Registry ID
    NCT04048850
    Conditions
    Hepatitis C; Hiv; Coinfection, HIV; Substance Use Disorders
    Interventions
    Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-20
    Completion
    2022-09-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Hiv; Coinfection, HIV; Substance Use Disorders
    InterventionElbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
    PhaseNot recorded
    Registry statusCompleted

  • Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet

    NCT03817619 · start 2019-03-28

    Registered record
    Registry ID
    NCT03817619
    Conditions
    Hepatitis C; Deglutition Disorders
    Interventions
    Zepatier whole tablet; Zepatier crushed tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-03-28
    Completion
    2019-07-30
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Deglutition Disorders
    InterventionZepatier whole tablet; Zepatier crushed tablet
    PhasePhase 1
    Registry statusCompleted

  • Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

    NCT03723824 · start 2019-02-14

    Registered record
    Registry ID
    NCT03723824
    Conditions
    Chronic Hepatitis c; Liver Transplant Infection; Kidney Transplant Infection
    Interventions
    grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-02-14
    Completion
    2021-03-13
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis c; Liver Transplant Infection; Kidney Transplant Infection
    Interventiongrazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
    PhasePhase 4
    Registry statusTerminated

  • A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

    NCT03791814 · start 2019-01-01

    Registered record
    Registry ID
    NCT03791814
    Conditions
    Hepatitis C
    Interventions
    Zepatier
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-01-01
    Completion
    2019-06-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionZepatier
    PhasePhase 4
    Registry statusWithdrawn

  • Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients

    NCT03496233 · start 2018-09-19

    Registered record
    Registry ID
    NCT03496233
    Conditions
    Chronic HCV Hepatitis
    Interventions
    Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-19
    Completion
    2020-06-20
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HCV Hepatitis
    InterventionElbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
    PhasePhase 3
    Registry statusCompleted

  • Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

    NCT03026023 · start 2018-08-01

    Registered record
    Registry ID
    NCT03026023
    Conditions
    Cardiac Transplant Disorder; Hepatitis C
    Interventions
    Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-08-01
    Completion
    2021-06-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Transplant Disorder; Hepatitis C
    InterventionCombindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
    PhasePhase 4
    Registry statusWithdrawn

  • A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

    NCT03585101 · start 2018-08

    Registered record
    Registry ID
    NCT03585101
    Conditions
    Hepatitis C
    Interventions
    Elbasvir/grazoprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-08
    Completion
    2020-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionElbasvir/grazoprevir
    PhasePhase 4
    Registry statusWithdrawn

  • Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

    NCT03578640 · start 2018-07-01

    Registered record
    Registry ID
    NCT03578640
    Conditions
    Hepatitis C, Chronic
    Interventions
    Elbasvir, Grazoprevir 50-100Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-01
    Completion
    2020-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionElbasvir, Grazoprevir 50-100Mg Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • EBR/GZR for HCV-1b Patients Receiving Hemodialysis

    NCT03420300 · start 2018-06-05

    Registered record
    Registry ID
    NCT03420300
    Conditions
    Hepatitis C
    Interventions
    EBR/GZR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-06-05
    Completion
    2020-02-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionEBR/GZR
    PhasePhase 4
    Registry statusCompleted

  • Hepatitis C (HCV) Cure and Kidney Health

    NCT03407703 · start 2018-03-27

    Registered record
    Registry ID
    NCT03407703
    Conditions
    Hepatitis C
    Interventions
    Elbasvir / Grazoprevir Oral Tablet [Zepatier]
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-03-27
    Completion
    2019-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionElbasvir / Grazoprevir Oral Tablet [Zepatier]
    PhaseNot recorded
    Registry statusUnknown

  • The Dublin Zepatier Study

    NCT02895958 · start 2018-03-15

    Registered record
    Registry ID
    NCT02895958
    Conditions
    Hepatitis C
    Interventions
    Zepatier
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-03-15
    Completion
    2019-12-06
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionZepatier
    PhasePhase 4
    Registry statusTerminated

  • Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy

    NCT03433326 · start 2018-03-01

    Registered record
    Registry ID
    NCT03433326
    Conditions
    Hepatitis C; Cryoglobulinaemic Glomerulonephritis
    Interventions
    Elbasvir/Grazoprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-03-01
    Completion
    2018-12-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Cryoglobulinaemic Glomerulonephritis
    InterventionElbasvir/Grazoprevir
    PhaseNot recorded
    Registry statusUnknown

  • Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

    NCT03359746 · start 2017-12-15

    Registered record
    Registry ID
    NCT03359746
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir/Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-12-15
    Completion
    2018-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir/Elbasvir
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection

    NCT03098121 · start 2017-10-20

    Registered record
    Registry ID
    NCT03098121
    Conditions
    Chronic Hepatitis C
    Interventions
    grazoprevir and elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-20
    Completion
    2018-11-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    Interventiongrazoprevir and elbasvir
    PhasePhase 4
    Registry statusCompleted